Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI North America CPhI North America
Not Confirmed
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Not Confirmed
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Not Confirmed
Not Confirmed
27-30 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Industry Trade Show
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Industry Trade Show
Not Confirmed
27-30 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels
16 Nov 2023
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/fda-panel-urges-acrotech-speed-up-study-cancer-drugs-2023-11-16/
24 Nov 2022
// INDIANPHARMAPOST
https://www.indianpharmapost.com/news/evive-enters-license-agreement-with-acrotech-biopharma-to-commercialize-ryzneuta-in-us-13335
24 Sep 2021
// Z. Brennan ENDPTS
https://endpts.com/fdas-cancer-drug-advisors-will-review-2-more-dangling-accelerated-approvals-for-multiple-myeloma-leukemia/
26 Apr 2021
// BUSINESSWIRE
https://www.businesswire.com/news/home/20210426005126/en/Acrotech-Biopharma-Announces-the-Publication-of-Data-From-a-Phase-1-Study-of-BELEODAQ%C2%AE-belinostat-Combined-With-Standard-CHOP-Bel-CHOP-in-Patients-With-Previously-Untreated-Peripheral-T-cell-Lymphoma
26 Apr 2021
// BUSINESSWIRE
Details:
The partnership aims for the manufacturing and advancement of iTolerance's Streptavidin-FasL (SA-FasL) fusion protein, a crucial component of the proprietary iTOL-100 platform technology towards first in human clinical study for lead program, iTOL-102.
Lead Product(s): Pralatrexate
Therapeutic Area: Oncology Brand Name: Folotyn
Study Phase: Approved FDFProduct Type: Cytotoxic Drug
Sponsor: CASI Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 08, 2023
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : CASI Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The partnership aims for the manufacturing and advancement of iTolerance's Streptavidin-FasL (SA-FasL) fusion protein, a crucial component of the proprietary iTOL-100 platform technology towards first in human clinical study for lead program, iTOL-102.
Product Name : Folotyn
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
January 08, 2023
ABOUT THIS PAGE